Literature DB >> 10545522

Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice.

B K McConnell1, K A Jones, D Fatkin, L H Arroyo, R T Lee, O Aristizabal, D H Turnbull, D Georgakopoulos, D Kass, M Bond, H Niimura, F J Schoen, D Conner, D A Fischman, C E Seidman, J G Seidman, D H Fischman.   

Abstract

To elucidate the role of cardiac myosin-binding protein-C (MyBP-C) in myocardial structure and function, we have produced mice expressing altered forms of this sarcomere protein. The engineered mutations encode truncated forms of MyBP-C in which the cardiac myosin heavy chain-binding and titin-binding domain has been replaced with novel amino acid residues. Analogous heterozygous defects in humans cause hypertrophic cardiomyopathy. Mice that are homozygous for the mutated MyBP-C alleles express less than 10% of truncated protein in M-bands of otherwise normal sarcomeres. Homozygous mice bearing mutated MyBP-C alleles are viable but exhibit neonatal onset of a progressive dilated cardiomyopathy with prominent histopathology of myocyte hypertrophy, myofibrillar disarray, fibrosis, and dystrophic calcification. Echocardiography of homozygous mutant mice showed left ventricular dilation and reduced contractile function at birth; myocardial hypertrophy increased as the animals matured. Left-ventricular pressure-volume analyses in adult homozygous mutant mice demonstrated depressed systolic contractility with diastolic dysfunction. These data revise our understanding of the role that MyBP-C plays in myofibrillogenesis during cardiac development and indicate the importance of this protein for long-term sarcomere function and normal cardiac morphology. We also propose that mice bearing homozygous familial hypertrophic cardiomyopathy-causing mutations may provide useful tools for predicting the severity of disease that these mutations will cause in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545522      PMCID: PMC409819          DOI: 10.1172/JCI7377

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C.

Authors:  M Gruen; M Gautel
Journal:  J Mol Biol       Date:  1999-02-26       Impact factor: 5.469

2.  Troponin I phosphorylation in spontaneously hypertensive rat heart: effect of beta-adrenergic stimulation.

Authors:  B K McConnell; C S Moravec; I Morano; M Bond
Journal:  Am J Physiol       Date:  1997-09

3.  Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.

Authors:  T Kubota; C F McTiernan; C S Frye; S E Slawson; B H Lemster; A P Koretsky; A J Demetris; A M Feldman
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

4.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy.

Authors:  L Carrier; G Bonne; E Bährend; B Yu; P Richard; F Niel; B Hainque; C Cruaud; F Gary; S Labeit; J B Bouhour; O Dubourg; M Desnos; A A Hagège; R J Trent; M Komajda; M Fiszman; K Schwartz
Journal:  Circ Res       Date:  1997-03       Impact factor: 17.367

5.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.

Authors:  H Niimura; L L Bachinski; S Sangwatanaroj; H Watkins; A E Chudley; W McKenna; A Kristinsson; R Roberts; M Sole; B J Maron; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

6.  Troponin I phosphorylation and myofilament calcium sensitivity during decompensated cardiac hypertrophy.

Authors:  B K McConnell; C S Moravec; M Bond
Journal:  Am J Physiol       Date:  1998-02

7.  Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart.

Authors:  W K Jones; I L Grupp; T Doetschman; G Grupp; H Osinska; T E Hewett; G Boivin; J Gulick; W A Ng; J Robbins
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

8.  Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein.

Authors:  W Rottbauer; M Gautel; J Zehelein; S Labeit; W M Franz; C Fischer; B Vollrath; G Mall; R Dietz; W Kübler; H A Katus
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

9.  Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice.

Authors:  M A Sussman; S Welch; N Cambon; R Klevitsky; T E Hewett; R Price; S A Witt; T R Kimball
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

10.  Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.

Authors:  T Ogawa; W Linz; M Stevenson; B G Bruneau; M L Kuroski de Bold; J H Chen; H Eid; B A Schölkens; A J de Bold
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

View more
  95 in total

1.  Experimental Modeling Supports a Role for MyBP-HL as a Novel Myofilament Component in Arrhythmia and Dilated Cardiomyopathy.

Authors:  David Y Barefield; Megan J Puckelwartz; Ellis Y Kim; Lisa D Wilsbacher; Andy H Vo; Emily A Waters; Judy U Earley; Michele Hadhazy; Lisa Dellefave-Castillo; Lorenzo L Pesce; Elizabeth M McNally
Journal:  Circulation       Date:  2017-08-04       Impact factor: 29.690

Review 2.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

3.  The challenge of molecular medicine: complexity versus Occam's razor.

Authors:  Eric A Sobie; Silvia Guatimosim; Long-Sheng Song; W J Lederer
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies.

Authors:  Kenneth R Chien
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 5.  Role of animal models in HCM research.

Authors:  Rhian Shephard; Christopher Semsarian
Journal:  J Cardiovasc Transl Res       Date:  2009-08-07       Impact factor: 4.132

Review 6.  The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors:  Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal:  J Vet Cardiol       Date:  2015-12       Impact factor: 1.701

Review 7.  MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.

Authors:  Diederik W D Kuster; Sakthivel Sadayappan
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

8.  Cardiac myosin binding protein-C phosphorylation in a {beta}-myosin heavy chain background.

Authors:  Sakthivel Sadayappan; James Gulick; Raisa Klevitsky; John N Lorenz; Michelle Sargent; Jeffery D Molkentin; Jeffrey Robbins
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

9.  Cardiac myosin binding protein C phosphorylation is cardioprotective.

Authors:  Sakthivel Sadayappan; Hanna Osinska; Raisa Klevitsky; John N Lorenz; Michelle Sargent; Jeffrey D Molkentin; Christine E Seidman; Jonathan G Seidman; Jeffrey Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

Review 10.  Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.

Authors:  Amelia A Glazier; Andrea Thompson; Sharlene M Day
Journal:  Pflugers Arch       Date:  2018-11-20       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.